-   Training & Support

[Expand/Collapse all sections]Expand all

This document outlines details of PBS-subsidised ruxolitinib for
patients with myelofibrosis (MF).

Myelofibrosis and listing dates

Myelofibrosis (MF) is a serious bone marrow disorder that disrupts the
body's normal production of blood cells.

Listing dates are:

-   ruxolitinib - February 2016

For more information, see Written Authority Required Drugs.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, contact details,
item and restriction codes, the PBS schedule and the Services Australia
website.

Related links

Tier 0 technical support - self-sufficiency

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Process telephone Authority approval application

Process written authority approval requests

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
